All In Biotech

Drug Trial Radar · NCT06232252

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Intravenous Doses of BI 765423 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)

Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

May 6, 2024

Primary completion

Apr 25, 2025

Study completion Apr 29, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jan 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics of BI 765423 in healthy male subjects.

Conditions

  • Healthy

Interventions

  • BI 765423Drug

    BI 765423

  • Placebo matching BI 765423Drug

    Placebo matching BI 765423

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects treated with BI 765423 who experience any treatment-emergent adverse event assessed as drug-related by the investigatorTime frame: up to 145 days for DG 1 and 2, up to 159 days for DG 3 and 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SGS Life Science Services - Clinical Research

    Edegem, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.